Esperion Therapeutics/ US29664W1053 /
2024-04-25 5:18:38 PM | Chg. -0.16 | Volume | Bid5:20:03 PM | Ask5:20:03 PM | High | Low |
---|---|---|---|---|---|---|
1.96USD | -7.33% | 18,376 Turnover: 36,565.98 |
1.95Bid Size: 500 | 1.96Ask Size: 1,400 | 2.14 | 1.95 |
GlobeNewswire
04-07
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (...
GlobeNewswire
03-27
One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors
GlobeNewswire
03-25
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & ...
GlobeNewswire
03-22
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiova...
GlobeNewswire
03-22
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose ...
GlobeNewswire
02-13
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
GlobeNewswire
01-23
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ ...
GlobeNewswire
01-03
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including...
GlobeNewswire
2023-12-13
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXL...
GlobeNewswire
2023-11-13
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at Ame...